1. El Ghaleb, Yousra, Flucher, Bernhard E. . CaV3.3 Channelopathies. In Handbook of experimental pharmacology, 279, 263-288. doi:10.1007/164_2022_631. https://pubmed.ncbi.nlm.nih.gov/36592228/
2. Xu, Wei, Liu, Yahui, Chen, Jianhua, Yi, Qizhong, Shi, Yongyong. 2017. Genetic risk between the CACNA1I gene and schizophrenia in Chinese Uygur population. In Hereditas, 155, 5. doi:10.1186/s41065-017-0037-1. https://pubmed.ncbi.nlm.nih.gov/28725167/
3. Maksemous, Neven, Blayney, Claire D, Sutherland, Heidi G, Adams, David J, Griffiths, Lyn R. 2022. Investigation of CACNA1I Cav3.3 Dysfunction in Hemiplegic Migraine. In Frontiers in molecular neuroscience, 15, 892820. doi:10.3389/fnmol.2022.892820. https://pubmed.ncbi.nlm.nih.gov/35928792/
4. Xie, Yijun, Huang, Di, Wei, Li, Luo, Xiong-Jian. 2018. Further evidence for the genetic association between CACNA1I and schizophrenia. In Hereditas, 155, 16. doi:10.1186/s41065-017-0054-0. https://pubmed.ncbi.nlm.nih.gov/29308060/
5. Andrade, A, Hope, J, Allen, A, Lipscombe, D, Pan, J Q. 2016. A rare schizophrenia risk variant of CACNA1I disrupts CaV3.3 channel activity. In Scientific reports, 6, 34233. doi:10.1038/srep34233. https://pubmed.ncbi.nlm.nih.gov/27756899/